LISINOPRIL AND HYDROCHLOROTHIAZIDE

N/A

Manufactured by Almatica Pharma Inc.

19,221 FDA adverse event reports analyzed

Last updated: 2026-04-14

About LISINOPRIL AND HYDROCHLOROTHIAZIDE

LISINOPRIL AND HYDROCHLOROTHIAZIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Almatica Pharma Inc.. The most commonly reported adverse reactions for LISINOPRIL AND HYDROCHLOROTHIAZIDE include NAUSEA, FATIGUE, DIARRHOEA, DRUG INEFFECTIVE, PAIN. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for LISINOPRIL AND HYDROCHLOROTHIAZIDE.

Top Adverse Reactions

NAUSEA671 reports
FATIGUE657 reports
DIARRHOEA592 reports
DRUG INEFFECTIVE553 reports
PAIN494 reports
DIZZINESS483 reports
DYSPNOEA436 reports
HEADACHE425 reports
ASTHENIA365 reports
VOMITING348 reports
COUGH336 reports
FALL332 reports
ARTHRALGIA327 reports
HYPERTENSION322 reports
MALAISE308 reports
ANGIOEDEMA292 reports
PRURITUS288 reports
PAIN IN EXTREMITY285 reports
INSOMNIA264 reports
HYPOTENSION257 reports
ANXIETY256 reports
WEIGHT DECREASED255 reports
RASH235 reports
CONSTIPATION230 reports
BACK PAIN223 reports
FEELING ABNORMAL218 reports
OFF LABEL USE216 reports
DEHYDRATION214 reports
ACUTE KIDNEY INJURY208 reports
BLOOD PRESSURE INCREASED207 reports
MUSCLE SPASMS204 reports
DEPRESSION197 reports
FLUSHING189 reports
PARAESTHESIA187 reports
PYREXIA187 reports
RENAL FAILURE187 reports
DEATH183 reports
WEIGHT INCREASED177 reports
DECREASED APPETITE174 reports
CHEST PAIN171 reports
PNEUMONIA171 reports
ABDOMINAL PAIN169 reports
BLOOD GLUCOSE INCREASED162 reports
SOMNOLENCE161 reports
RENAL FAILURE ACUTE159 reports
ABDOMINAL DISCOMFORT158 reports
GAIT DISTURBANCE157 reports
ANAEMIA155 reports
URINARY TRACT INFECTION155 reports
HYPOAESTHESIA153 reports
ABDOMINAL PAIN UPPER149 reports
CONDITION AGGRAVATED149 reports
MYOCARDIAL INFARCTION147 reports
CONFUSIONAL STATE146 reports
MYALGIA144 reports
CEREBROVASCULAR ACCIDENT142 reports
TREMOR136 reports
HYPONATRAEMIA135 reports
OEDEMA PERIPHERAL133 reports
PRODUCT DOSE OMISSION ISSUE131 reports
CHRONIC KIDNEY DISEASE130 reports
HYPERHIDROSIS130 reports
DRUG INTERACTION128 reports
VISION BLURRED127 reports
ALOPECIA126 reports
SYNCOPE126 reports
ERYTHEMA124 reports
LOSS OF CONSCIOUSNESS123 reports
DRUG DOSE OMISSION120 reports
HOT FLUSH119 reports
PERIPHERAL SWELLING118 reports
DRUG HYPERSENSITIVITY113 reports
MUSCULAR WEAKNESS106 reports
PSORIASIS105 reports
DIABETES MELLITUS104 reports
GASTROOESOPHAGEAL REFLUX DISEASE104 reports
INJECTION SITE PAIN104 reports
NASOPHARYNGITIS100 reports
DYSPEPSIA99 reports
MEMORY IMPAIRMENT99 reports
COVID 1998 reports
HYPOKALAEMIA97 reports
CARDIAC FAILURE CONGESTIVE96 reports
HYPERSENSITIVITY94 reports
NEUROPATHY PERIPHERAL94 reports
URTICARIA93 reports
BALANCE DISORDER92 reports
PALPITATIONS92 reports
DYSPHAGIA88 reports
FEELING HOT88 reports
CHEST DISCOMFORT87 reports
ATRIAL FIBRILLATION86 reports
CHILLS85 reports
EMOTIONAL DISTRESS83 reports
HAEMOGLOBIN DECREASED82 reports
ABDOMINAL DISTENSION81 reports
RENAL IMPAIRMENT80 reports
SWOLLEN TONGUE79 reports
PRODUCT QUALITY ISSUE78 reports
PULMONARY EMBOLISM78 reports

Report Outcomes

Out of 9,952 classified reports for LISINOPRIL AND HYDROCHLOROTHIAZIDE:

Serious 60.9%Non-Serious 39.1%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female5,323 (56.3%)
Male4,122 (43.6%)
Unknown8 (0.1%)

Reports by Age

Age 64220 reports
Age 69208 reports
Age 65197 reports
Age 61196 reports
Age 68192 reports
Age 60190 reports
Age 62186 reports
Age 67184 reports
Age 63182 reports
Age 56168 reports
Age 66168 reports
Age 58167 reports
Age 54166 reports
Age 70164 reports
Age 57161 reports
Age 59160 reports
Age 71155 reports
Age 73149 reports
Age 52147 reports
Age 72144 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with LISINOPRIL AND HYDROCHLOROTHIAZIDE?

This profile reflects 19,221 FDA FAERS reports that mention LISINOPRIL AND HYDROCHLOROTHIAZIDE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for LISINOPRIL AND HYDROCHLOROTHIAZIDE?

Frequently reported terms in FAERS include NAUSEA, FATIGUE, DIARRHOEA, DRUG INEFFECTIVE, PAIN, DIZZINESS. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures LISINOPRIL AND HYDROCHLOROTHIAZIDE?

Labeling and FAERS entries often list Almatica Pharma Inc. in connection with LISINOPRIL AND HYDROCHLOROTHIAZIDE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.